Ani Pharmaceuticals INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
ANI Pharmaceuticals announced a 25.9% increase in net revenues for the second quarter of 2026, driven by significant growth in its Rare Disease and Brands segment.
NASDAQ
ANI Pharmaceuticals announces a 20.5% increase in net revenues for Q1 2026, driven by its Rare Disease and Brands segment, with significant growth in Cortrophin Gel and ILUVIEN sales.
NASDAQ
ANI Pharmaceuticals delivered significant revenue and net income growth in Q3 2025, driven by its Rare Disease and Brands segment and recent acquisitions.
NASDAQ
ANI Pharmaceuticals reports significant revenue and profit growth in Q2 2025, driven by its Rare Disease and Brands segments and successful integration of Alimera Sciences.
NASDAQ
10-Q: ANI Pharmaceuticals Reports Strong Q1 2025 Results Driven by Alimera Acquisition and Generic Growth
ANI Pharmaceuticals' Q1 2025 net revenues increased by 43.4% year-over-year, driven by the acquisition of Alimera and growth in generic pharmaceutical products.
NASDAQ
ANI Pharmaceuticals' Q3 2024 results reflect a net loss, increased operating expenses, and the impact of the recent Alimera acquisition, alongside a significant increase in rare disease revenue.
NASDAQ
ANI Pharmaceuticals' Q2 2024 results show increased revenue driven by rare disease products, but a net loss due to acquisition costs and other factors.
NASDAQ
ANI Pharmaceuticals saw a significant increase in revenue and profitability in the first quarter of 2024, driven by strong performance in its rare disease segment and a gain from the sale of a former manufacturing facility.